98%
921
2 minutes
20
Oculocutaneous albinism (OCA) is an autosomal recessive syndromic and non-syndromic defect with deficient or a complete lack of the melanin pigment. The characteristics of OCA appears in skin, hair, and eyes with variable degree of pigmentation. Clinical manifestations of OCA include nystagmus, photophobia, reduced visual acuity, hypo-plastic macula, and iris trans-illumination. There are eight OCA types (OCA1-8) documented with non-syndromic characteristics. Molecular studies identified seven genes linked to the OCA phenotype (, , , , , and ) and one locus (OCA5) in consanguineous and sporadic albinism. The complications of OCA result in skin cancer and variable syndromes such as Hermansky-Pudlak syndrome (HPS) Chediak-Higashi syndrome (CHS). In the Pakistani population, autosomal recessive non-syndromic OCA is common and is associated with a large number of consanguineous families, and mutations in genes of non-syndromic types are reported. This review highlights the updates on the genetic mutation of OCA genes reported from Pakistani families. Several studies reported the genetic mutations in OCA1, OCA2, OCA3, OCA4, and OCA6 albinism in Pakistani families. A locus, OCA5, was also reported from the Pakistani population, but the gene has not been identified. A new type of OCA8 was identified due to the gene mutation, and it is also reviewed here.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9222488 | PMC |
http://dx.doi.org/10.3390/genes13061072 | DOI Listing |
Clin Case Rep
September 2025
Children's Medical Center, Pediatrics Center of Excellence Tehran University of Medical Sciences Tehran Iran.
Pyridoxine-dependent epilepsy (PDE) is a rare, autosomal recessive neurometabolic disorder characterized by intractable seizures responsive to pyridoxine. We present the case of an 11-day-old female neonate with a history of refractory multifocal seizures beginning on day three of life, accompanied by hepatomegaly, metabolic acidosis, elevated serum ammonia and lactate, and abnormal liver function tests. Despite multiple antiepileptic and metabolic treatments, seizures persisted, and the infant developed progressive metabolic disturbances.
View Article and Find Full Text PDFGenet Med Open
July 2025
Faculty of Biology Medicine and Health, University of Manchester, United Kingdom.
Purpose: Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive disorder. This study aimed to analyze the genotype distribution of FCS-causing genes in the United Kingdom.
Methods: Data were anonymously collated from 2 genetic testing laboratories providing national genetic diagnosis services for severe hypertriglyceridemia in the United Kingdom.
Front Med (Lausanne)
August 2025
Department of Dermatology, The National Center for the Integration of Traditional Chinese and Western Medicine, China-Japan Friendship Hospital, Beijing, China.
[This corrects the article DOI: 10.3389/fmed.2025.
View Article and Find Full Text PDFTremor Other Hyperkinet Mov (N Y)
September 2025
Movement Disorders and Neurodegenerative Diseases Unit, Hospital Civil de Guadalajara "Fray Antonio Alcalde", Guadalajara, Mexico.
Clinical Vignette: RNA polymerase III subunit A (POLR3A) related disorders are a group of heterogeneous diseases with a recessive autosomic inheritance. These disorders manifest with distinct clinical features like ataxia, spasticity, hypodontia, hypogonadism, mental retardation and progressive motor decline.
Clinical Dilemma: POLR3A gene mutation can manifest with parkinsonism, dystonia, ataxia and tremor.
J Ophthalmol
August 2025
Department of Ophthalmology, Duke University, Durham, North Carolina, USA.
To investigate whether supplementation with dietary antioxidants has an effect on the yearly progression rate of atrophic lesions in autosomal recessive Stargardt disease (STGD1), as derived from fundus autofluorescence (FAF). Retrospective study of patients with molecularly confirmed STGD1 aged ≥ 6 years at baseline and presence of an atrophic lesion of ≥ 250 μm in diameter, who underwent FAF imaging between 01/01/2010 and 10/31/2023. Patients were grouped into supplement takers and nontakers based on the daily intake of lutein, zeaxanthin, saffron, and N-acetylcysteine.
View Article and Find Full Text PDF